NIFTY 50 22795.9 ▼ (0.51%)
NIFTY NEXT 50 60466.8 ▼ (0.94%)
NIFTY 100 23274.05 ▼ (0.59%)
NIFTY MIDCAP 100 50486.2 ▼ (1.32%)
NIFTY SMALLCAP 100 15636.9 ▼ (0.7%)
NIFTY SMALLCAP 250 14683.4 ▼ (0.57%)
NIFTY MIDCAP SELECT 11198.9 ▼ (1.69%)
NIFTY TOTAL MARKET 11634.25 ▼ (0.67%)
NIFTY BANK 48981.2 ▼ (0.72%)
SENSEX 75311.06 ▼ (0.56%)
BSE BANKEX 55718.18 ▼ (0.82%)

Mercury Laboratories : Q4 2024 Financial Quarterly Report : YoY Sales Down 10.62 %, QoQ Up 1.47 %

July 1, 2024July 1, 2024| adminadmin| 0 Comments| 9:45 am
Image is loading
Categories:

Share the post "Mercury Laboratories : Q4 2024 Financial Quarterly Report : YoY Sales Down 10.62 %, QoQ Up 1.47 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company’s sales declined by -10.62 % over the year, substantial increase in net sales/revenue by 1.47 %.
  • Income over the Year and quarter: There has been decline in other income over the past year which is -4.65 %, Marginal increase in other income during this quarter, up by 127.78%.
  • Profit over the Year and quarter: Significant improvement in profitability for Mercury Laboratories Limited. Notable increase of 420.44 % in net profit Year to Year, Mercury Laboratories Limited’s profitability increased by 54.41 % in this quarter.
  • EPS over the Year and quarter: EPS increased by 421.97 % Year to Year. EPS increased by 54.56 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of Mercury Laboratories Limited”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 19.431 Cr Rs. 17.115 Cr Rs. 17.367 Cr + 1.47 % -10.62 %
Expenses Rs. 18.39 Cr Rs. 14.89 Cr Rs. 14.71 Cr -1.21 % -20.01 %
Operating Profit Rs. 1.04 Cr Rs. 2.23 Cr Rs. 2.66 Cr + 19.28 % + 155.77 %
OPM % 5.35 % 13.03 % 15.32 % + 2.29 % + 9.97 %
Other Income Rs. 0.43 Cr Rs. 0.18 Cr Rs. 0.41 Cr + 127.78 % -4.65 %
Interest Rs. 0.1 Cr Rs. 0.1 Cr Rs. 0.1 Cr + 0 % + 0 %
Depreciation Rs. 0.62 Cr Rs. 0.72 Cr Rs. 0.72 Cr + 0 % + 16.13 %
Profit before tax Rs. 0.75 Cr Rs. 1.59 Cr Rs. 2.25 Cr + 41.51 % + 200 %
Tax % 54.31 % 22.07 % 15.07 % -7 % -39.24 %
Net Profit Rs. 0.37 Cr Rs. 1.24 Cr Rs. 1.91 Cr + 54.03 % + 416.22 %
EPS in Rs Rs. 3.05 Rs. 10.3 Rs. 15.92 + 54.56 % + 421.97 %


Today, we’re looking at Mercury Laboratories Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -10.62 %. However, it did see a marginal increase of 1.47 % from the previous quarter. Expenses decreased slightly by -1.21 % quarter-on-quarter, aligning with the annual decline of -20.01 %. Operating profit, while up 155.77 % compared to last year, faced a quarter-on-quarter increase of 19.28 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 9.97 %, but an expansion of 2.29 % sequentially. Other income rose by 127.78 % compared to the last quarter, despite an annual decline of -4.65 %. Interest expenses surged remarkably by 0 % from the previous quarter, yet the year-over-year increase remains at a moderate 0 %. Depreciation costs climbed by 0 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 16.13 %. Profit before tax grew annually by 200 % but saw an increase from the preceding quarter by 41.51 %.
Tax expenses as a percentage of profits decreased slightly by -39.24 % compared to last year, with a more notable quarter-on-quarter decrease of -7 %. Net profit rose by 416.22 % year-on-year but experienced a 54.03 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 421.97 % but a quarterly rise of 54.56 %. In summary, Mercury Laboratories Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 19.431 Cr Rs. 17.115 Cr Rs. 17.367 Cr + 1.47 % -10.62 %
Expenses Rs. 18.39 Cr Rs. 14.89 Cr Rs. 14.71 Cr -1.21 % -20.01 %
Operating Profit Rs. 1.04 Cr Rs. 2.23 Cr Rs. 2.66 Cr + 19.28 % + 155.77 %
Net Profit Rs. 0.37 Cr Rs. 1.24 Cr Rs. 1.91 Cr + 54.03 % + 416.22 %
EPS in Rs Rs. 3.05 Rs. 10.3 Rs. 15.92 + 54.56 % + 421.97 %


In reviewing Mercury Laboratories Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -10.62 % year-on-year, however, there was a minor increase of 1.47 % from the previous quarter. Expenses decreased by -20.01 % compared to the previous year, with a decrease of -1.21 % quarter-on-quarter. Operating Profit surged by 155.77 % annually, and saw a 19.28 % increase from the last quarter.
Net Profit showed yearly increase of 416.22 %, and experienced a 54.03 % increase from the previous quarter. Earnings Per Share (EPS) rose by 421.97 % annually, however rose by 54.56 % compared to the last quarter. In essence, while Mercury Laboratories Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Mercury Laboratories “]

Related Post